ArticleBMC cancer2025
Management and survival outcomes of desmoplastic small round cell tumor: a retrospective cohort study from a tertiary cancer center.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Case Report: Refractory desmoplastic small round cell tumor: a report of a molecularly confirmed case withFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesmoplastic small round cell tumor (DSRCT) is a highly aggressive and uncommon sarcoma with a dismal clinical outcome. Western cohorts have reported clinical outcomes, but there is minimal evidence from the Indian context. This study examined the clinical features, management, and outcomes of DSRCT patients at a tertiary cancer center in India.
methodsWe retrospectively reviewed medical records of 25 patients with pathologically confirmed DSRCT treated between 2014 and 2023 at Regional Cancer Centre (RCC), Trivandrum. Survival outcomes were estimated using the Kaplan–Meier method and prognostic factors by Cox regression analysis.
resultsThe median age at diagnosis was 29 years (range 14–53 years), with a male predominance (N = 24, 96%). Vincristine, doxorubicin, cyclophosphamide plus ifosfamide, and etoposide (VDC + IE) was the first-line regimen in 84% (N = 21) and was associated with the longest median overall survival (OS) of 25 months. Surgery was performed in 36% (N = 9) (all R2 resection) of patients and significantly improved OS (28.0 vs. 13.5 months; p = 0.0093). Median OS for the cohort was 22.0 months, with 1-, 2-, and 3-year survival rates of 63.0%, 44.2%, and 14.7%, respectively. Median progression-free survival (PFS) was 16.0 months after first-line and 5.5 months after second-line therapy. Increasing age was independently associated with poorer survival (hazard ratio [HR] 1.09; p = 0.0165).
conclusionAlthough DSRCT may initially respond to chemotherapy, the benefit diminishes with successive lines, and long-term outcomes remain poor. Surgical resection, when feasible, offers a survival advantage, but there is an urgent need for evidence-based novel therapeutic strategies.
trial registrationNot applicable. This was a retrospective study of routinely collected clinical data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.